Veracyte

Veracyte, Inc., founded in South San Francisco, focuses on developing molecular tests for oncology to enhance diagnostic accuracy. The company's mission is to provide exceptional cancer care through exceptional diagnostics. Veracyte offers a range of genomic classifiers, including the Afirma® Genomic Sequencing Classifier for thyroid cancer, Decipher® Prostate and Bladder Genomic Classifiers, Prosigna® Breast Cancer Assay, and Envisia® Genomic Classifier for interstitial lung disease (ILD). Their services target healthcare and molecular diagnostic companies across the United States.

Notable affiliations include the recent acquisition of C2i Genomics, expanding Veracyte's capabilities in precision oncology. Key achievements include the widespread adoption of their genomic classifiers, which have significantly improved diagnostic accuracy and patient outcomes in cancer care. Veracyte's impact is evident in its contribution to the early and precise diagnosis of various cancers, thereby enabling more effective treatment plans and improving overall patient care.